CervoMed Presents Interim Data on Neflamapimod's Impact on Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia
Rapid Read

CervoMed Presents Interim Data on Neflamapimod's Impact on Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia

What's Happening? CervoMed Inc. presented 24-week interim biomarker data from the U.S. cohort of its Phase 2a clinical trial for neflamapimod, an oral p38α inhibitor, in patients with nonfluent variant primary progressive aphasia (nfvPPA). The findings, presented at the 19th Clinical Trials on Alzhe
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.